A review of tramadol for dogs, examining controlled-substance regulations, the canine M1 metabolizer problem, drug interactions like serotonin syndrome, and 3,793 FDA reports.

For over a decade, tramadol has been one of the most widely prescribed analgesics in veterinary medicine. It is routinely dispensed to dogs for acute post-operative pain, cancer-related pain, and chronic osteoarthritic discomfort—frequently as part of a multimodal pain management plan alongside non-steroidal anti-inflammatory drugs (NSAIDs) or gabapentin.

However, the veterinary community's understanding of tramadol has undergone a major shift. Pharmacokinetic and clinical efficacy studies have revealed that dogs process tramadol in a highly species-specific manner that renders oral administration far less reliable than previously assumed. Indeed, the 2022 AAHA Pain Management Guidelines for Dogs and Cats explicitly state that oral tramadol has not been shown to be effective postoperatively in dogs and place it in the lowest tier of recommended analgesics. Furthermore, its classification as a DEA Schedule IV controlled substance in 2014 has introduced strict regulatory requirements for storage, logs, and refills in the clinic.

To help pet owners and veterinary teams understand the clinical reality of tramadol, this article provides a detailed, evidence-first review of the drug. We examine its mechanism of action, explain the canine M1 metabolizer problem that limits its efficacy, outline common and serious side effects, map critical drug-drug interactions (including serotonin syndrome risk), review controlled-substance handling requirements, and analyze 3,793 unique adverse-event reports submitted to the FDA's Center for Veterinary Medicine.

Direct Answer: Efficacy and Safety Profile of Tramadol in Dogs

Oral tramadol is a synthetic, centrally acting opioid analgesic prescribed extra-label (off-label) in dogs. While it is widely used, recent clinical evidence indicates that oral tramadol is an unreliable and often ineffective standalone pain reliever in dogs.

The key clinical and safety realities of tramadol in dogs include:

The Efficacy Controversy: Tramadol is a "prodrug." To provide significant opioid-mediated pain relief, it must be metabolized by the liver into its active form, O-desmethyltramadol (M1). Because dogs lack sufficient levels of the specific liver enzyme (canine CYP2D15) required for this conversion, they produce extremely low, variable, and transient concentrations of the active M1 metabolite. Consequently, oral tramadol behaves primarily as a weak serotonin and norepinephrine reuptake inhibitor rather than a true opioid in dogs, and the 2022 AAHA Guidelines place it in the lowest tier of efficacy.
Common Side Effects: The most frequent side effects are somnolence (sedation), mild gastrointestinal upset (vomiting, soft stool, or diarrhea), and decreased appetite (anorexia). Dysphoria (whining, pacing, or agitation) can also occur.
High-Risk Drug Interactions: Tramadol must never be combined with Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine, Monoamine Oxidase Inhibitors (MAOIs) like selegiline, or tricyclic antidepressants like clomipramine. Because tramadol increases serotonin levels in the brain, combining it with these drugs carries a high risk of triggering serotonin syndrome, a life-threatening neurotoxic crisis.
Controlled-Substance Handling: In 2014, the DEA rescheduled tramadol as a Schedule IV controlled substance. This requires clinics to store it in a double-locked safe, maintain detailed run logs, limit refills to five within a six-month period, and comply with state prescription monitoring programs.
FDA Adverse-Event Profile: An analysis of the openFDA animal adverse-event reporting database reveals 3,793 unique reports naming tramadol, with 1,791 flagged as serious. However, because tramadol is typically prescribed to geriatric dogs, oncology patients, or postoperative patients receiving multiple medications, these counts reflect the sick population and polypharmacy reporting habits rather than proof that tramadol caused the events.

Efficacy: The Canine M1 Metabolizer and CYP2D15 Problem

To understand why tramadol is no longer considered a first-line analgesic for dogs, we must look at its pharmacology. Tramadol is a synthetic analog of codeine. It is a racemic mixture of two enantiomers:

(+)-tramadol: Inhibits serotonin reuptake and stimulates serotonin release.
(-)-tramadol: Inhibits norepinephrine reuptake.

Both enantiomers are weak agonists at the mu-opioid receptor (μ-receptor). However, the parent drug's affinity for the mu-receptor is roughly 6,000 times weaker than morphine.

For tramadol to deliver meaningful, opioid-grade pain relief, it must undergo phase-I metabolism (demethylation) in the liver to produce O-desmethyltramadol (the M1 metabolite). The M1 metabolite has a mu-receptor binding affinity that is 200 times stronger than the parent tramadol molecule.

[Parent Tramadol (Very Weak Opioid)]
               ||
               ||  (Canine CYP2D15 Liver Enzyme — Extremely Low in Dogs)
               \/
 [M1 Active Metabolite (Strong Opioid)]

The Canine Genetic Limit

In humans, the liver enzyme CYP2D6 converts tramadol into the active M1 metabolite, which binds tightly to the mu-opioid receptor. Dogs do not have CYP2D6; instead they use a species-specific ortholog named canine CYP2D15, which is the enzyme responsible for O-demethylation of tramadol to M1.

Pharmacokinetic and in-vitro liver-microsome studies have demonstrated that:

A Competing Pathway Steals the Drug: Dogs route a large share of tramadol down a different metabolic pathway — N-demethylation to the inactive M2 metabolite via the enzyme CYP2B11 (with help from CYP3A12). Because this competing pathway is so active in dogs, relatively little of each dose is shunted toward the active M1 metabolite in the first place.
Low and Variable Net M1 Production: Net circulating M1 concentrations after an oral dose are low and highly variable between individual dogs. (In-vitro, dog liver microsomes actually form M1 faster than human liver microsomes — but they form it about 3.9× more slowly than cat liver, and the competing M2 pathway plus rapid clearance erase that advantage in the living dog.)
Rapid Clearance: Even when the M1 metabolite is produced, its half-life in dogs is extremely short — the canine liver clears tramadol and M1 so quickly that the active metabolite cannot accumulate to the sustained therapeutic concentrations seen in humans.
Variable Oral Exposure: The concentration curves of M1 after oral dosing are flat and highly variable between individual dogs, meaning some dogs produce clinically trivial amounts of active drug.

Because of this rapid clearance and low production, oral tramadol does not achieve therapeutic opioid levels in the canine brain. Any mild analgesic effect a dog experiences is almost entirely due to the parent drug's monoaminergic activity (inhibiting serotonin and norepinephrine reuptake). While monoaminergic activity can help manage chronic neuropathic pain (similar to how tricyclic antidepressants are used for pain in humans), it is entirely inadequate for acute, inflammatory, or surgical pain.

In Contrast: The Feline Metabolic Pathway ("Cats are Not Small Dogs")

The genetic limit of canine CYP2D15 is highlighted when compared to feline metabolism. Cats possess different hepatic enzyme systems that convert tramadol to the active M1 metabolite highly efficiently.

High Bioavailability: Unlike dogs, cats achieve high and sustained blood concentrations of M1 after oral dosing.
Opioid Efficacy: In feline patients, tramadol behaves as a true mu-opioid agonist, providing excellent postoperative and acute pain relief.
Side-Effect Risks: Because cats are highly sensitive to mu-opioid stimulation, they are also far more prone to opioid-related side effects. A cat receiving tramadol may show significant pupillary dilation (mydriasis), sedation, salivation, dysphoric pacing, and marked behavioral changes. This contrast is a classic example of species-specific pharmacology in veterinary medicine. It explains why a drug that is highly effective and potent in cats is clinically unreliable in dogs.

Efficacy Trial Evidence

This pharmacology explains why a major clinical study published in the Journal of the American Veterinary Medical Association (JAVMA) evaluated oral tramadol for osteoarthritic pain in dogs and found that it provided no clinical benefit compared to a placebo. In the double-blind, randomized crossover study, 35 dogs with osteoarthritis were treated with carprofen (an NSAID), oral tramadol, or a placebo. The investigators measured pain and joint function using objective force-platform gait analysis (vertical ground reaction forces). While carprofen showed significant, measurable pain relief and improved weight-bearing, tramadol was clinically indistinguishable from the placebo.

Adverse Effects and Clinical Monitoring

While oral tramadol is a weak pain reliever in dogs, it remains a active drug with a distinct side-effect profile. Clinicians and owners must monitor patients for both common, dose-dependent side effects and rare, serious toxicities.

Common Adverse Effects

Sedation and Lethargy: The most frequent side effect reported by owners. It is dose-dependent and typically peaks 2 to 3 hours after administration. In older dogs or those already receiving other sedating medications (such as gabapentin), the sedation can be profound, leading to difficulty rising or unsteadiness.
Gastrointestinal Distress: Vomiting, salivation (nausea), and soft stool or diarrhea are common. These signs are typically self-limiting and resolve if the medication is discontinued or the dose is reduced.
Decreased Appetite (Anorexia): Tramadol can cause mild to moderate inappetence, which is particularly challenging in oncology patients where maintaining caloric intake is critical.
Dysphoria and Agitation: Opioids can cause dysphoria (vocalizing, pacing, inability to rest, dilated pupils) in some dogs. Because the M1 metabolite level is low, this is less common with tramadol than with pure mu-agonists like hydromorphone, but it remains a distinct clinical possibility.

Serious Risks and Contraindications

Seizure Threshold Reduction: Like in humans, tramadol reduces the seizure threshold. It is contraindicated in dogs with a history of epilepsy or those receiving other medications that lower the seizure threshold.
No Abrupt Withdrawal: If a dog has been receiving high-dose tramadol long-term (such as for chronic cancer pain), the drug must not be stopped abruptly. Sudden withdrawal can trigger rebound pain, severe anxiety, and tremors. The dose should be tapered down gradually over 7 to 10 days.

Critical Drug-Drug Interactions: The Serotonin Syndrome Risk

Because tramadol's primary active mechanism in dogs is monoaminergic (modulating serotonin and norepinephrine) rather than opioid-driven, it carries a high risk of drug-drug interactions that can lead to life-threatening complications.

+---------------------------------------------------------------------------------+
|                           HIGH-RISK INTERACTIONS                                |
+-----------------------------------+---------------------------------------------+
| Co-Prescribed Drug                | Clinical Risk / Complication                |
+-----------------------------------+---------------------------------------------+
| SSRIs (Fluoxetine)                | Serotonin Syndrome (Hyperthermia, Seizures) |
| Tricyclics (Clomipramine)         | Serotonin Syndrome (Tremors, Tachycardia)   |
| MAOIs (Selegiline)                | Severe Neurotoxicity (Contraindicated)      |
| Trazodone                         | Serotonin Overload (Monitor Closely)        |
| Gabapentin                        | Enhanced CNS Depression (Ataxia, Sedation)  |
+-----------------------------------+---------------------------------------------+

Serotonin Syndrome

Serotonin syndrome is a toxic state caused by an excess of serotonin in the central nervous system. It occurs when tramadol is administered alongside other serotonergic medications:

Selective Serotonin Reuptake Inhibitors (SSRIs): e.g., fluoxetine (prescribed for behavior modification).
Tricyclic Antidepressants (TCAs): e.g., clomipramine (prescribed for separation anxiety).
Monoamine Oxidase Inhibitors (MAOIs): e.g., selegiline (prescribed for canine cognitive dysfunction).
Serotonin Antagonist and Reuptake Inhibitors (SARIs): e.g., trazodone (frequently prescribed for situational anxiety or post-operative confinement).

Clinical Signs of Serotonin Syndrome in Dogs:

Neuromuscular: Muscle tremors, rigidity, hyperreflexia, ataxia, and seizures.
Autonomic: Hyperthermia (dangerously high body temperature), tachycardia (rapid heart rate), mydriasis (dilated pupils), salivation, and diarrhea.
Mental State: Extreme agitation, pacing, vocalizing, and disorientation.

If a dog exhibits tremors, a rapid heart rate, or a spiked temperature while taking tramadol alongside trazodone or fluoxetine, stop the medications immediately and seek emergency veterinary care.

Multimodal Combinations: Tramadol + Gabapentin + NSAIDs

Veterinarians frequently combine tramadol with gabapentin and an NSAID (such as carprofen or meloxicam) for multimodal osteoarthritis management.

The Gabapentin Interaction: Gabapentin and tramadol do not have a direct pharmacologic contraindication, but they do have additive CNS depressant effects. Combining the two routinely results in significant sedation and ataxia, particularly during the first 3 to 5 days of therapy. Owners should be prepared for their dog to be wobbly and should protect them from stairs or slippery floors.
The NSAID Interaction: There is no direct drug interaction between tramadol and NSAIDs, making this a safe combination. Because NSAIDs target inflammatory pathways and tramadol targets central reuptake pathways, the combination is pharmacologically sound, though the NSAID performs the vast majority of the anti-nociceptive work.

DEA Schedule IV Controlled-Substance Status and Regulations

For many years, tramadol was unregulated under the federal Controlled Substances Act. However, due to rising rates of human abuse, diversion, and dependence, the U.S. Drug Enforcement Administration (DEA) placed tramadol into Schedule IV effective August 18, 2014.

This rescheduling placed significant administrative and legal requirements on veterinary practices:

Security and Storage: In veterinary clinics, bulk tramadol stock must be stored in a securely locked cabinet or a double-locked safe, identical to how diazepam or phenobarbital is stored. It cannot be kept on open pharmacy shelves.
Detailed Logging: Every dose of tramadol dispensed or administered in the clinic must be recorded in the controlled-substance log. The log must include the date, patient name, client name, dose administered, amount discarded, and the initials of the prescribing veterinarian.
Prescription and Refill Limits:
- Under federal law, Schedule IV prescriptions may only be refilled up to five times within a six-month period from the date of issue.
- Prescriptions expire six months after the written date.
- In many states, the dispensing of tramadol must be reported to the state's Prescription Monitoring Program (PMP/PDMP) daily, allowing regulators to track potential "vet shopping" by owners seeking to divert the drug for human use.
Clinic Staff Training: Veterinary technicians and receptionists must be trained on how to handle refill requests and recognize warning signs of drug diversion (e.g., clients claiming their dog "lost" their X-ray-confirmed pain medication repeatedly, or requesting refills significantly ahead of schedule).

openFDA Adverse Event Data Analysis

Because tramadol is typically prescribed off-label in dogs, there is no official pre-market safety database specific to veterinary medicine. To evaluate its real-world safety profile, we analyzed the raw, de-identified reports from the FDA's Center for Veterinary Medicine (CVM) adverse-event database.

As of the July 5, 2026 data export, the openFDA database holds 3,793 unique adverse-event reports naming tramadol as an active ingredient.

Species and Severity Distribution

The distribution of reports across species and outcomes is highly concentrated:

Total Unique Reports: 3,793
  - Dogs: 3,741 reports (98.6%)
  - Cats: 34 reports (0.9%)
  - Humans: 10 reports (0.3%)
  - Other Species (Parrot, Rabbit, etc.): 8 reports (0.2%)

Serious-AE Flag:
  - Serious Adverse Events: 1,791 reports (47.2%)
  - Non-Serious: 1,970 reports (51.9%)
  - Unclassified / Blank: 32 reports (0.8%)

A detailed evaluation of the outcome fields reveals that these reports include:

Ongoing (unresolved at the time of reporting): 1,288 cases
Recovered / Normal: 979 cases
Outcome Unknown: 790 cases
Euthanized: 417 cases
Died: 238 cases
Recovered with Sequela: 70 cases

Critical Epidemiological Caveat: A reader looking at these counts might assume tramadol is unusually dangerous — but the numbers are report-attributes, not measures of causation. The FDA adverse-event database is a passive surveillance system. Veterinarians and manufacturers are far more likely to file a report when something serious happens, so mild, expected effects (transient sleepiness, minor drooling) are heavily under-reported and the serious share is inflated relative to true incidence.

Furthermore, tramadol is typically given to older, sick, or cancer patients alongside many other medications (polypharmacy). In these geriatric populations, natural disease progression (renal failure, tumor metastasis, age-related decline) is frequently co-reported as an adverse drug event regardless of whether tramadol caused the symptom. The deaths and euthanasias in this dataset overwhelmingly reflect the end-stage underlying disease of the population receiving the drug, not tramadol toxicity.

Polypharmacy and Co-Drug Analysis

In the 3,793 reports, tramadol was rarely administered alone. 99.5% of reports list at least one other co-prescribed medication, and the average report names roughly 5 active ingredients. The most common co-prescribed drug classes in the database are:

NSAIDs (Carprofen, Meloxicam, Deracoxib, Firocoxib, Robenacoxib, Grapiprant, and others): Present in roughly 2,357 reports. Because NSAIDs are the cornerstone of osteoarthritis therapy, they are routinely combined with tramadol. This complicates the attribution of gastrointestinal side effects (like vomiting or diarrhea) and liver enzyme elevations (ALT/SAP), which are well-documented side effects of NSAID therapy.
Gabapentin: Present in roughly 790 reports. Co-prescribing these two medications is standard practice for multimodal neuropathic pain control, which explains the high frequency of reports listing both sedation and ataxia.
Parasiticides (heartworm and flea/tick preventives): These appear frequently across the dataset as well, representing background usage in the patient population rather than drug-drug interactions.

When analyzing side effects like elevated liver enzymes (ALT, SAP) or renal signs, clinicians must recognize that these are almost always associated with the underlying disease state or co-administered NSAID therapy, rather than direct tramadol toxicity. Tramadol itself is metabolized by the liver and excreted by the kidneys, but it is not considered primary organ-toxic at standard clinical doses.

Top 10 Reported Reactions

The most frequent clinical reactions listed in the 3,793 unique tramadol reports are:

Vomiting: 825 reports (Reflecting acute gastric irritation or central nausea).
Lethargy / CNS Depression: 705 reports (Confirming the drug's primary sedating effect).
Other Abnormal Test Result NOS: 508 reports (Typically representing baseline bloodwork variations in geriatric patients).
Anorexia (Appetite Loss): 475 reports.
Diarrhoea: 456 reports.
Death by Euthanasia: 411 reports (Reflecting the end-stage cancer or osteoarthritic populations receiving the drug).
Elevated Alanine Aminotransferase (ALT): 355 reports (Representing liver enzyme changes, though these dogs were almost always co-prescribed NSAIDs).
Emesis (Nausea/Retching): 327 reports.
Elevated Serum Alkaline Phosphatase (SAP): 306 reports.
Lack of Efficacy - NOS: 305 reports (Factual confirmation of the clinical efficacy controversy—veterinarians and owners reporting that the drug failed to relieve the dog's pain).

FAQs

Is tramadol a strong painkiller for dogs?

No. In dogs, oral tramadol is a weak and unreliable pain reliever. While it is a strong opioid in humans, dogs lack the specific liver enzyme (CYP2D15) required to convert tramadol into its active opioid form (M1). As a result, tramadol does not activate opioid pain receptors in dogs and provides only mild, antidepressant-like pain modulation. It should never be used as the sole pain reliever for moderate to severe pain, such as after surgery.

Can I give my dog tramadol and gabapentin together?

Yes, this is a very common combination used for chronic arthritis or neuropathic pain. However, because both drugs depress the central nervous system, combining them will cause significant sedation and wobbly walking (ataxia). Monitor your dog closely, block access to stairs, and use rugs on slippery floors to prevent falls. The sedation typically improves after a few days of joint therapy.

Why was tramadol made a controlled substance (Schedule IV)?

Tramadol was rescheduled as a Schedule IV controlled substance in 2014 due to rising rates of human abuse, addiction, and diversion. Because tramadol acts as a true, addictive opioid in humans, the DEA restricted refills, instituted mandatory locked storage in clinics, and required detailed usage logging to prevent individuals from diverting their pets' prescriptions.

What are the signs of serotonin syndrome in a dog on tramadol?

Signs of serotonin syndrome include muscle tremors, rigid limbs, loss of coordination (ataxia), pacing, vocalizing, dilated pupils, a rapid heart rate, and a dangerously high body temperature (hyperthermia). This is a medical emergency that occurs if tramadol is combined with other serotonergic medications like trazodone, fluoxetine, or clomipramine.

Sources

Gruen ME, et al. 2022 AAHA Pain Management Guidelines for Dogs and Cats. Journal of the American Animal Hospital Association. 2022;58(2):55-76. https://www.aaha.org/aaha-guidelines/2022-aaha-pain-management-guidelines-for-dogs-and-cats/
Kukanich B, Papich MG. Pharmacokinetics of tramadol and its active metabolite O-desmethyltramadol in dogs. Journal of Veterinary Pharmacology and Therapeutics. 2004;27(4):239-246. https://pubmed.ncbi.nlm.nih.gov/15320932/
Budsberg SC, et al. Lack of effectiveness of oral tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with osteoarthritis. Journal of the American Veterinary Medical Association. 2018;252(4):427-432. https://avmajournals.avma.org/view/journals/javma/252/4/javma.252.4.427.xml
U.S. Food and Drug Administration. Center for Veterinary Medicine (CVM) Adverse Event Reporting Database (openFDA animal-veterinary event reports, July 5, 2026 export). https://open.fda.gov/animal-veterinary-event/
U.S. Drug Enforcement Administration (DEA). Scheduling of Tramadol (Final Rule, 2014). Federal Register. https://www.federalregister.gov/documents/2014/07/02/2014-15548/schedules-of-controlled-substances-placement-of-tramadol-into-schedule-iv
National Institutes of Health (NIH). PMC5118633 — Tramadol metabolism and pharmacokinetics. https://pmc.ncbi.nlm.nih.gov/articles/PMC5118633/

Vet Med Guide

Tramadol for Dogs: Controlled Status, the M1 Problem, and 3,793 FDA Reports